Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1995 Mar;39(3):333–336. doi: 10.1111/j.1365-2125.1995.tb04458.x

Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia.

N Cutler 1, J Sramek 1, A Veroff 1, G Block 1, L Stauffer 1, C Lines 1
PMCID: PMC1365013  PMID: 7619678

Abstract

The effects of equi-efficacious doses of the cholesterol-lowering drugs simvastatin (20 mg day-1) and pravastatin (40 mg day-1) on tests of cognitive function were investigated in a double-blind, placebo-controlled, 2-period (4 weeks per period), incomplete block, crossover study of 36 patients (24 per treatment) with hypercholesterolaemia. After 4 weeks neither of the active treatments differed significantly from placebo on any cognitive measure.

Full text

PDF
333

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Botti R. E., Triscari J., Pan H. Y., Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991 Jun;14(3):256–261. doi: 10.1097/00002826-199106000-00010. [DOI] [PubMed] [Google Scholar]
  2. Broks P., Preston G. C., Traub M., Poppleton P., Ward C., Stahl S. M. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia. 1988;26(5):685–700. doi: 10.1016/0028-3932(88)90004-8. [DOI] [PubMed] [Google Scholar]
  3. Eckernäs S. A., Roos B. E., Kvidal P., Eriksson L. O., Block G. A., Neafus R. P., Haigh J. R. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993 Mar;35(3):284–289. [PMC free article] [PubMed] [Google Scholar]
  4. Gengo F., Gabos C., Miller J. K. The pharmacodynamics of diphenhydramine-induced drowsiness and changes in mental performance. Clin Pharmacol Ther. 1989 Jan;45(1):15–21. doi: 10.1038/clpt.1989.3. [DOI] [PubMed] [Google Scholar]
  5. Harrison R. W., Ashton C. H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994 Mar;37(3):231–236. doi: 10.1111/j.1365-2125.1994.tb04268.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Illingworth D. R., Erkelens D. W., Keller U., Thompson G. R., Tikkanen M. J. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet. 1994 Jun 18;343(8912):1554–1555. doi: 10.1016/s0140-6736(94)92945-9. [DOI] [PubMed] [Google Scholar]
  7. Keech A., Collins R., MacMahon S., Armitage J., Lawson A., Wallendszus K., Fatemian M., Kearney E., Lyon V., Mindell J. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J. 1994 Feb;15(2):255–269. doi: 10.1093/oxfordjournals.eurheartj.a060485. [DOI] [PubMed] [Google Scholar]
  8. Preston G. C., Broks P., Traub M., Ward C., Poppleton P., Stahl S. M. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology (Berl) 1988;95(2):208–215. doi: 10.1007/BF00174511. [DOI] [PubMed] [Google Scholar]
  9. Triscari J., Markowitz J. S., McGovern M. W. Pravastatin and lovastatin in cerebrospinal fluid. Clin Neuropharmacol. 1993 Dec;16(6):559–560. doi: 10.1097/00002826-199312000-00010. [DOI] [PubMed] [Google Scholar]
  10. Veroff A. E., Cutler N. R., Sramek J. J., Prior P. L., Mickelson W., Hartman J. K. A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery. J Geriatr Psychiatry Neurol. 1991 Oct-Dec;4(4):211–217. doi: 10.1177/089198879100400406. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES